On May 11th, CF PHARMTECH (02652) spent HKD 186,000 to repurchase 8,500 shares.
Changfeng Pharmaceutical (02652) announced that on May 11, 2026, it will spend HK$186,000 to repurchase 8,500 shares.
CF PHARMTECH (02652) announced on May 11, 2026, that it will spend HKD 186,000 to repurchase 8,500 shares.
Related Articles
CONCORD HC GP (02453): Jiang Li has been elected as a worker representative director.
New Stock News | Shenzhen Mindray Bio-Medical Electronics (300760.SZ) once again submits application to Hong Kong Stock Exchange, aiming to become the leading company in China's medical equipment industry.
CHINA BLUECHEM (03983): He Qunhui resigns as Executive Director.
CONCORD HC GP (02453): Jiang Li has been elected as a worker representative director.
New Stock News | Shenzhen Mindray Bio-Medical Electronics (300760.SZ) once again submits application to Hong Kong Stock Exchange, aiming to become the leading company in China's medical equipment industry.
CHINA BLUECHEM (03983): He Qunhui resigns as Executive Director.
RECOMMEND
Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
11/05/2026
HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
11/05/2026
The Chip Stock Frenzy Is Still Accelerating
11/05/2026
